|
|
| Martins,D.M.F.; Vidal,F.C.B.; Souza,R.D.M.; Brusaca,S.A.; Brito,L.M.O.. |
| The CYP2D6 enzyme is crucial for the metabolism of tamoxifen. The CYP2D6 gene is highly polymorphic, and individuals can be extensive, intermediate, or poor tamoxifen metabolizers. The aim of this study was to determine the frequencies of the CYP2D6 *3, *4, and *10 alleles in women with breast cancer who were treated with tamoxifen and analyze the association of enzyme activity with prognostic factors and disease-free survival. We observed a high frequency of CYP2D6 *10, with an allelic frequency of 0.14 (14.4%). The *3 allele was not present in the studied population, and *4 had an allelic frequency of 0.13 (13.8%). We conclude that patients with reduced CYP2D6 activity did not present worse tumor characteristics or decreased disease-free survival than... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Tamoxifen; Cytochrome P450 2D6; Breast cancer; Genetic polymorphisms; Prognostic factors; Disease-free survival. |
| Ano: 2014 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2014001101008 |
| |
